Compare LLY & JPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LLY | JPM |
|---|---|---|
| Founded | 1876 | 1799 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 950.7B | 879.5B |
| IPO Year | N/A | N/A |
| Metric | LLY | JPM |
|---|---|---|
| Price | $1,021.40 | $300.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 13 |
| Target Price | ★ $1,104.00 | $333.31 |
| AVG Volume (30 Days) | 2.7M | ★ 11.5M |
| Earning Date | 02-04-2026 | 01-13-2026 |
| Dividend Yield | 0.67% | ★ 2.00% |
| EPS Growth | ★ 121.02 | 1.37 |
| EPS | ★ 20.44 | 20.02 |
| Revenue | $59,419,800,000.00 | ★ $168,235,000,000.00 |
| Revenue This Year | $42.97 | $17.09 |
| Revenue Next Year | $21.50 | $3.56 |
| P/E Ratio | $50.85 | ★ $15.00 |
| Revenue Growth | ★ 45.41 | 0.88 |
| 52 Week Low | $623.78 | $202.16 |
| 52 Week High | $1,133.95 | $337.25 |
| Indicator | LLY | JPM |
|---|---|---|
| Relative Strength Index (RSI) | 41.86 | 38.00 |
| Support Level | $1,015.96 | $296.51 |
| Resistance Level | $1,073.39 | $301.97 |
| Average True Range (ATR) | 32.99 | 5.98 |
| MACD | -6.32 | -2.24 |
| Stochastic Oscillator | 13.30 | 11.61 |
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
JPMorgan Chase is one of the largest and most complex financial institutions in the United States, with more than $4 trillion in assets. It is organized into four major segments: consumer and community banking, corporate and investment banking, commercial banking, and asset and wealth management. JPMorgan operates and is subject to regulation in multiple countries.